Clinical trials
Crohn's Disease, Active clinical trials
Below are recruiting crohn's disease, active clinical trials, each written for real people, not researchers. We’re tracking 199 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT04187820Recruiting
Acupuncture for mild to moderate Crohn’s flare
This trial tests whether acupuncture can help calm an active Crohn’s disease flare that is mild to moderate. It may be an option if standard Crohn’s medicines like steroids, immunosuppressors, and anti-TNF drugs are not working for you or you can’t tolerate them.
Shanghai, Shanghai MunicipalityAges 16–70 - NCT07078994RecruitingPhase 2
Study of a new drug for moderate to severe Crohn's disease
This trial tests a new medicine called BCD-261 for people with moderate to severe Crohn's disease that has not responded well to other treatments. It aims to see if the drug can reduce symptoms and inflammation.
Barnaul, Altayskiy KrayAges 18–75 - NCT05928039RecruitingPhase 4
Choosing the best first biologic for Crohn’s in the ileum
This Phase 4 trial tests which type of biologic medicine works best as the first treatment for people with moderate-to-severe Crohn’s that mainly affects the ileum. It may help you and your care team choose a more effective first option, based on which strategy leads to better control of symptoms and intestinal inflammation.
Calgary, AlbertaAges 18 years+ - NCT06937099RecruitingPhase 3
Testing two drugs for Crohn's with weight issues
This trial tests two study drugs, mirikizumab and tirzepatide, in people with moderate to severe Crohn's disease who also have overweight or obesity. The goal is to see if these treatments can help control Crohn's symptoms and inflammation.
Dothan, AlabamaAges 18–70 - NCT06925061RecruitingPhase 2
Testing EXL01 to prevent Crohn's disease return after surgery
This study tests a new oral treatment called EXL01 to see if it can prevent Crohn's disease from coming back after surgery to remove part of the small and large intestine. It may be an option if you are not planning to use strong immune-suppressing drugs (except anti-TNF) in the next 6 months.
Clermont-FerrandAges 18 years+ - NCT06819891RecruitingPhase 3
Study of afimkibart for active Crohn's disease
This trial tests a new medicine called afimkibart for people with moderately to severely active Crohn's disease that has not responded well to other treatments. It aims to see if the medicine can safely reduce inflammation and improve symptoms.
Dothan, AlabamaAges 16–80 - NCT06819878RecruitingPhase 3
Afimkibart for moderate to severe Crohn's disease
This study tests an experimental drug called afimkibart for people with moderate to severe Crohn's disease who haven't responded well to other treatments. The goal is to see if the drug can help control symptoms and reduce inflammation over time.
Dothan, AlabamaAges 16–80 - NCT06742385Recruiting
Smartphone app to monitor active inflammatory bowel disease
This study tests a smartphone app (SEMEIA) to help monitor people with active Crohn's disease or ulcerative colitis. It may help you track your symptoms and stay in touch with your doctor without needing as many office visits.
Neuilly-sur-Seine, FranceAges 18–80 - NCT06722456Enrolling by invitation
Better ways to detect active IBD
This study tests non-invasive tools to find active inflammation in people with Crohn's disease or ulcerative colitis. You may need to give extra stool samples before your colonoscopy and calprotectin test.
Sherbrooke, QuebecAges 18 years+ - NCT06538649RecruitingEarly Phase 1
Testing statins for Crohn's disease before and after surgery
This study tests whether taking a statin (a cholesterol-lowering medicine) before and after surgery for Crohn's disease can help improve outcomes. It's for people with a specific type of Crohn's that causes narrowing in the small intestine and who are already scheduled for surgery.
Stanford, CaliforniaAges 18–80 - NCT06456593RecruitingPhase 2
Obefazimod for moderate to severe Crohn's disease
This trial tests an experimental oral medication called obefazimod for people with moderate to severe Crohn's disease. It aims to see if the drug can reduce inflammation and improve symptoms when other treatments have not worked well.
Fairhope, AlabamaAges 18–75 - NCT06332534RecruitingPhase 3
Upadacitinib in children with moderate to severe Crohn's disease
This study tests an oral pill called upadacitinib for children with moderate to severe Crohn's disease that hasn't responded well to other treatments. It aims to see if the medicine can reduce inflammation and improve symptoms safely.
Oakland, CaliforniaAges 2–17 - NCT06274554RecruitingPhase 3
Testing Antifungal Therapy for Crohn's Disease
This study tests whether adding an antifungal drug (fluconazole) to standard Crohn's disease treatment helps improve symptoms. It's for people with mild to moderate Crohn's who have not used antifungal medications recently.
New York, New YorkAges 18 years+ - NCT06257706RecruitingPhase 4
Healing the bowel wall in Crohn's disease with vedolizumab
This study tests whether a medicine called vedolizumab can help heal all layers of the bowel wall in Crohn's disease. It uses a special ultrasound to see inside the bowel, aiming for deeper healing than usual.
Los Angeles, CaliforniaAges 18–80 - NCT06233461RecruitingPhase 2
A study of TAK-279 for Crohn's disease
This study tests an oral medication called TAK-279 to see if it can safely reduce inflammation in the bowel for people with moderate to severe Crohn's disease who haven't had success with other treatments.
Murrieta, CaliforniaAges 18–75 - NCT06226883RecruitingPhase 2
Testing MORF-057 for moderate to severe Crohn's disease
This study tests an oral medicine called MORF-057 for people with moderate to severe Crohn's disease. It aims to see if the drug can reduce inflammation and improve symptoms for those who haven't had success with other treatments.
Lancaster, CaliforniaAges 18–85 - NCT06023030Recruiting
Observing how upadacitinib works for Crohn's disease in Japan
This study is for people with moderate to severe Crohn's disease who are starting a medication called upadacitinib. Researchers will watch how the disease changes over time and check for any side effects. It's an observational study, meaning you'll keep getting your regular treatment.
Anjo-shi, Aichi-kenAges 15 years+ - NCT05995353RecruitingPhase 3
Risankizumab for children with moderate to severe Crohn's
This study tests a new medicine called risankizumab for children with moderate to severe Crohn's disease. It is given as an IV infusion or a shot under the skin to see if it can reduce inflammation and improve symptoms.
Phoenix, ArizonaAges 2–17 - NCT05835973Recruiting
Study of sleep changes in people with inflammatory bowel disease
This study looks at how sleep patterns change in adults with inflammatory bowel disease (IBD) who are currently in remission. It may help researchers understand sleep issues in IBD and identify ways to improve care during symptom-free periods.
Clermont-FerrandAges 18–65 - NCT05923073RecruitingPhase 3
Guselkumab for children with active Crohn’s disease
This Phase 3 trial tests guselkumab to treat children with moderately to severely active Crohn’s disease and ongoing inflammation in the bowel. If you qualify, the study will check whether the medicine can improve symptoms and healing, especially in children who did not respond to other treatments.
Los Angeles, CaliforniaAges 2–17 - NCT05321758Recruiting
Stool transplant as first treatment for kids with Crohn’s
This study tests whether transferring healthy gut bacteria from stool into the colon can work as a first treatment for children newly diagnosed with mild-to-moderate Crohn’s disease. It may help reduce inflammation and improve symptoms, and it requires regular colonoscopy to monitor progress.
Wuhan, HubeiAges 2–16 - NCT05332639Recruiting
Risk tracking test for Crohn’s disease in teens
This study checks whether a personalized tool can estimate someone’s risk for Crohn’s disease before symptoms start. It may help families learn early risk and decide on next steps sooner.
Boston, MassachusettsAges 14 years+ - NCT03915262Recruiting
Active Crohn’s patients with possible pancreas enzyme problems
This study looks at how often people with active Crohn’s disease also have trouble digesting food because the pancreas may not release enough enzymes (exocrine pancreatic insufficiency). It may help doctors better recognize this hidden problem in people whose Crohn’s is currently active.
Pierre-BéniteAges 18 years+ - NCT04777656RecruitingPhase 3
Crohn’s exclusion diet plus usual care for kids
This study tests whether a specific “exclusion diet” (removing certain foods) added to standard treatment can better control unstable Crohn’s disease in children. It may help reduce inflammation and flare-ups when symptoms are not controlled by usual medicines.
BronAges 6–17
Hear when a new Crohn's Disease, Active trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for crohn's disease, active?
- Yes. Clin2 currently lists 199 recruiting crohn's disease, active studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a crohn's disease, active trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a crohn's disease, active trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.